Table 1.
Patient and treatment characteristics.
| Patients | N = 69 (100%) | |
|---|---|---|
| Age at CAR-T infusion | Median (years) | 61 (range 26–76) |
| Sex | Female | 26 (38%) |
| Disease Subtype | Diffuse Large B-Cell Lymphoma | 39 (57%) |
| Transformed Follicular Lymphoma | 16 (23%) | |
| High-grade Lymphoma | 13 (19%) | |
| Primary Mediastinal B-Cell Lymphoma | 1 (1%) | |
| Previous Lines of Therapy | 2 | 14 (20%) |
| 3 | 29 (42%) | |
| ≥4 | 26 (38%) | |
| B Symptoms at CAR-T Evaluation | Present | 7 (10%) |
| Absent | 61 (88%) | |
| Unknown | 1 (1%) | |
| LDH Level at CAR-T Evaluation | Elevated | 19 (28%) |
| Normal | 48 (70%) | |
| Not Evaluated | 2 (3%) | |
| CRP at CAR-T Infusion | >100 mg/L | 6 (9%) |
| 10-100 mg/L | 42 (61%) | |
| ≤10 mg/L | 21 (30%) | |
| Ferritin at CAR-T Infusion | Elevated | 25 (36%) |
| Normal | 44 (64%) | |
| Received Bridging Therapy | Yes | 44 (64%) |
| No | 25 (36%) |